Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call-To The Moon - Tiger Brokers Online Investing Community - To The Moon

Like
Comment
Favorite

Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Benzinga03-20

Bionano Genomics, Inc. (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.

Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.

On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.

Bionano Genomics shares closed at $1.12 on Thursday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

HC Wainwright & Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.
Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.
Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.

Considering buying BNGO stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Like

Report

Comment

empty

No comments yet

Most Discussed

7x24

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2620785328?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 15:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620785328","market":"hk","top_or_hot":-1,"title":"Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call","media":"Benzinga","content":"<html><body><p><strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a>, Inc.</strong> (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.</p>\n<p>Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.</p>\n<p>Bionano Genomics shares closed at $1.12 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.</li>\n<li>Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.</li>\n<li>Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.</li>\n</ul>\n<p>Considering buying BNGO stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"542\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBionano Genomics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2026-03-20 15:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><strong><a href=\"https://laohu8.com/S/BNGO\">Bionano Genomics</a>, Inc.</strong> (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.</p>\n<p>Analysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.</p>\n<p>On Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.</p>\n<p>Bionano Genomics shares closed at $1.12 on Thursday.</p>\n<p>Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.</p>\n<p>Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.</p>\n<ul>\n<li>HC Wainwright &amp; Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.</li>\n<li>Maxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.</li>\n<li>Scotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.</li>\n</ul>\n<p>Considering buying BNGO stock? Here’s what analysts think: </p>\n<figure><img decoding=\"async\" height=\"542\" loading=\"lazy\" sizes=\"(max-width: 1024px) 100vw, 1024px\" src=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png\" srcset=\"https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2026/03/20025502/image-448.png 1212w\" width=\"1024\"/></figure>\n<p><em>Photo via Shutterstock</em></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BNGO","symbol_name":"Bionano Genomics","start_time":0,"source_url":"https://www.benzinga.com/analyst-stock-ratings/price-target/26/03/51372905/bionano-genomics-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call","article_id":"2620785328","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620785328","pubTimestamp":1773993250,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Bionano Genomics, Inc. (BNGO) will release Q4 earnings on March 23. Analysts expect $1.40 loss per share on $7.85M revenue. Stock closed at $1.12.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BNGO":"Bionano Genomics"},"translate_title":"Bionano Genomics盈利迫在眉睫；这些最准确的分析师在收益看涨期权之前修改了预测","themeId":"11c8fbbf839f433c9d274cef5f173382","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNGO":1.5},"content_text":"Bionano Genomics, Inc. (NASDAQ:BNGO) will release earnings results for its fourth quarter, after the closing bell on Monday, March 23.\nAnalysts expect the San Diego, California-based company to report a quarterly loss at $1.40 per share on revenue of $7.85 million, according to data from Benzinga Pro.\nOn Jan. 12, Bionano Genomics said it expects fourth-quarter revenue of $7.8 million-$8.0 million and FY25 total revenue of $28.4 million-$28.6 million.\nBionano Genomics shares closed at $1.12 on Thursday.\nBenzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.\nLet's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.\n\nHC Wainwright & Co. analyst Yi Chen maintained a Buy rating and cut the price target from $11 to $7 on Nov. 24, 2025. This analyst has an accuracy rate of 65%.\nMaxim Group analyst Jason McCarthy upgraded the stock from Hold to Buy with a price target of $8 on May 20, 2025. This analyst has an accuracy rate of 44%.\nScotiabank analyst Sung Ji Nam maintained a Sector Perform rating and boosted the price target from $1 to $4 on April 2, 2025. This analyst has an accuracy rate of 57%.\n\nConsidering buying BNGO stock? Here’s what analysts think: \n\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}